Plasma IL-12/IFN-γ Axis Predicts Cognitive Trajectories in Cognitively Unimpaired Older Adults

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2021 Jun 23

PMID 34160128

Citations 35

Authors

Hyun-Sik Yang

Can Zhang

Becky C Carlyle

Sherri Y Zhen

Bianca A Trombetta

Aaron P Schultz

Jeremy J Pruzin

Colleen D Fitzpatrick

Wai-Ying W Yau

Dylan R Kirn

Dorene M Rentz

Steven E Arnold

Keith A Johnson

Reisa A Sperling

Jasmeer P Chhatwal

Rudolph E Tanzi

Affiliations

Soon will be listed here.

Abstract

Introduction: Immune dysregulation is implicated in neurodegeneration and altered cytokine levels are seen in people with dementia. However, whether cytokine levels are predictive of cognitive decline in cognitively unimpaired (CU) elderly, especially in the setting of elevated amyloid beta (Aβ), remains unclear.

Methods: We measured nine cytokines in the baseline plasma of 298 longitudinally followed CU elderly and assessed whether these measures were associated with cognitive decline, alone or synergistically with Aβ. We next examined associations between cytokine levels and neuroimaging biomarkers of Aβ/tau/neurodegeneration.

Results: Higher IL-12p70 was associated with slower cognitive decline in the setting of higher Aβ (false discovery rate [FDR] = 0.0023), whereas higher IFN-γ was associated with slower cognitive decline independent of Aβ (FDR = 0.013). Higher IL-12p70 was associated with less tau and neurodegeneration in participants with higher Aβ.

Discussion: Immune dysregulation is implicated in early-stage cognitive decline, and greater IL-12/IFN-γ axis activation may be protective against cognitive decline and early-stage AD progression.

Citing Articles

Age- and sex-associated alterations in hypothalamic mitochondrial bioenergetics and inflammatory-associated signaling in the 3xTg mouse model of Alzheimer's disease.

Adlimoghaddam A, Fontaine K, Albensi B Biol Sex Differ. 2024; 15(1):95.

PMID: 39587693 PMC: 11587679. DOI: 10.1186/s13293-024-00671-7.

Targeting Myeloperoxidase to Reduce Neuroinflammation in X-Linked Dystonia Parkinsonism.

Petrozziello T, Jalali Motlagh N, Monsanto R, Lei D, Murcar M, Penney E CNS Neurosci Ther. 2024; 30(11):e70109.

PMID: 39500625 PMC: 11537767. DOI: 10.1111/cns.70109.

Inflammaging and Brain Aging.

Jurcau M, Jurcau A, Cristian A, Hogea V, Diaconu R, Nunkoo V Int J Mol Sci. 2024; 25(19).

PMID: 39408862 PMC: 11476611. DOI: 10.3390/ijms251910535.

Cytokine dysregulation in amnestic mild cognitive impairment.

Tran-Chi V, Maes M, Nantachai G, Hemrungrojn S, Solmi M, Stoyanov D Sci Rep. 2024; 14(1):22486.

PMID: 39341896 PMC: 11439069. DOI: 10.1038/s41598-024-73099-z.

Profiling migration of human monocytes in response to chemotactic and barotactic guidance cues.

Hall C, Barr O, Delamare A, Burkholder A, Tsai A, Tian Y Cell Rep Methods. 2024; 4(9):100846.

PMID: 39241776 PMC: 11440068. DOI: 10.1016/j.crmeth.2024.100846.

References

Ewers M, Franzmeier N, Suarez-Calvet M, Morenas-Rodriguez E, Caballero M, Kleinberger G . Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med. 2019; 11(507). PMC: 7050285. DOI: 10.1126/scitranslmed.aav6221. View

Brosseron F, Kolbe C, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S . Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimers Dement. 2019; 16(2):292-304. DOI: 10.1016/j.jalz.2019.07.018. View

Ridker P . From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016; 118(1):145-56. PMC: 4793711. DOI: 10.1161/CIRCRESAHA.115.306656. View

Sims R, van der Lee S, Naj A, Bellenguez C, Badarinarayan N, Jakobsdottir J . Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017; 49(9):1373-1384. PMC: 5669039. DOI: 10.1038/ng.3916. View

Darweesh S, Wolters F, Ikram M, de Wolf F, Bos D, Hofman A . Inflammatory markers and the risk of dementia and Alzheimer's disease: A meta-analysis. Alzheimers Dement. 2018; 14(11):1450-1459. DOI: 10.1016/j.jalz.2018.02.014. View

Cherry J, Olschowka J, OBanion M . Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014; 11:98. PMC: 4060849. DOI: 10.1186/1742-2094-11-98. View

Ahola-Olli A, Wurtz P, Havulinna A, Aalto K, Pitkanen N, Lehtimaki T . Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet. 2016; 100(1):40-50. PMC: 5223028. DOI: 10.1016/j.ajhg.2016.11.007. View

Finucane H, Reshef Y, Anttila V, Slowikowski K, Gusev A, Byrnes A . Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat Genet. 2018; 50(4):621-629. PMC: 5896795. DOI: 10.1038/s41588-018-0081-4. View

Ransohoff R . A polarizing question: do M1 and M2 microglia exist?. Nat Neurosci. 2016; 19(8):987-91. DOI: 10.1038/nn.4338. View

10.

Papp K, Rentz D, Orlovsky I, Sperling R, Mormino E . Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y). 2017; 3(4):668-677. PMC: 5726754. DOI: 10.1016/j.trci.2017.10.004. View

11.

Andreone B, Przybyla L, Llapashtica C, Rana A, Davis S, van Lengerich B . Alzheimer's-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nat Neurosci. 2020; 23(8):927-938. DOI: 10.1038/s41593-020-0650-6. View

12.

Griciuc A, Serrano-Pozo A, Parrado A, Lesinski A, Asselin C, Mullin K . Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013; 78(4):631-43. PMC: 3706457. DOI: 10.1016/j.neuron.2013.04.014. View

13.

Gagliano S, Pouget J, Hardy J, Knight J, Barnes M, Ryten M . Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases. Ann Clin Transl Neurol. 2017; 3(12):924-933. PMC: 5224821. DOI: 10.1002/acn3.369. View

14.

Heppner F, Ransohoff R, Becher B . Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015; 16(6):358-72. DOI: 10.1038/nrn3880. View

15.

Shen X, Niu L, Wang Y, Cao X, Liu Q, Tan L . Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019; 90(5):590-598. DOI: 10.1136/jnnp-2018-319148. View

16.

Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H . CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018; 91(9):e867-e877. PMC: 6133624. DOI: 10.1212/WNL.0000000000006082. View

17.

Moir R, Lathe R, Tanzi R . The antimicrobial protection hypothesis of Alzheimer's disease. Alzheimers Dement. 2018; 14(12):1602-1614. DOI: 10.1016/j.jalz.2018.06.3040. View

18.

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

19.

Martinez F, Gordon S . The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13. PMC: 3944738. DOI: 10.12703/P6-13. View

20.

Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan M . Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008; 83(5):623-32. PMC: 2668052. DOI: 10.1016/j.ajhg.2008.10.008. View